VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Reports Third Quarter 2018 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with
View HTML
Toggle Summary VIVUS Adds Two New Members to the Board of Directors
Karen Ferrell and Edward A. Kangas Expand VIVUS’ Board to Nine Members CAMPBELL, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that Karen Ferrell and Edward A. Kangas have been appointed to VIVUS’ board of
View HTML
Toggle Summary VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018
CAMPBELL, Calif. , Oct. 26, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2018 after the market close on Thursday, November 1, 2018. The company will host a conference call beginning
View HTML
Toggle Summary VIVUS to Present at the BIO Investor Forum on October 17, 2018
CAMPBELL, Calif. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that
View HTML
Toggle Summary VIVUS Regains Compliance with Nasdaq Listing Requirements
CAMPBELL, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it has regained full compliance with Nasdaq
View HTML
Toggle Summary VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up
CAMPBELL, Calif. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. , (NASDAQ: VVUS), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it will make a presentation at the Fourth Annual Robins
View HTML
Toggle Summary VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb
-Fundraising event at AT&T Stadium on September 22 supports the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation - CAMPBELL, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the
View HTML
Toggle Summary VIVUS Announces 1-for-10 Reverse Stock Split
CAMPBELL, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that the Company’s stockholders approved a reverse stock split. Effective September 10, 2018 , the Company will enact a 1-for-10 reverse stock split of its
View HTML
Toggle Summary VIVUS Reports Data Supporting the Cardiovascular Safety of Qsymia®
-Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - CAMPBELL, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, has reported encouraging data from a
View HTML
Toggle Summary VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018
CAMPBELL, Calif. , Aug. 22, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that
View HTML